Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
More info
16 Dec 2020
Menarini Group awarded the coveted XV Transatlantic Award from American Chamber of Commerce in Italy
Read more
07 Dec 2020
Menarini Announces Results from New Preclinical Studies on MEN1611 for the Treatment of Breast Cancer at the 2020 San Antonio Breast Cancer Symposium
Menarini Group announced today that it will present the results of two different preclinical studies on MEN1611 at the upcoming 2020 San Antonio Breast Cancer Symposium, which will be held virtually on December 8-11.
Read more
01 Dec 2020
Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial
SEL24/MEN1703 is being Evaluated for the Treatment of Acute Myeloid Leukemia (AML) Poster Accepted for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
Read more
13 Nov 2020
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
Read more
17 Sep 2020
Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Read more
16 Sep 2020
Menarini Ricerche Announces Initiation of Cohort Expansion for the Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Menarini Ricerche, the R&D division of the Menarini Group, announced today that it has treated the first patient in Europe for the cohort expansion part of DIAMOND-01 clinical trial
Read more
Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last